Any current/future new fundraising through debt or equity?

The transcript does not explicitly mention any current or planned fundraising through debt or equity. However, the company is set to benefit from government incentive schemes, including a GST-linked incentive and a capital interest subvention on loans, which will reduce interest costs by approximately 600 basis points. There is discussion of investments in new facilities, such as the Jammu plant, designed to last 40-50 years, but no direct mention of new fundraising activities. Management refrained from giving consolidated revenue guidance, indicating a cautious outlook without highlighting sp

Any current/future capex/capital investment/strategic investment?

Innova Captab has recently commercialized its Jammu facility in January 2025, representing a significant capital investment. The Jammu facility is expected to generate incremental revenue of ₹400-500 crores in FY26, ramping up further to peak utilization by FY28. The company is focused on expanding capacity and product portfolio through this new facility, with an estimated peak revenue potential of around ₹2,000 crores at full utilization. The Jammu facility is compliant with stringent future-ready regulations, designed with a 40-50 year vision. Innova Captab is eligible for Central Government

Future growth expectations in sales/revenue/volumes?

Innova Captab expects continued growth driven by existing volume growth and the new Jammu facility. Jammu facility revenue is estimated between ₹400-₹500 crores in FY '26, with potential to reach ₹1,000 crores in 2-3 years. Peak utilization for Jammu plant expected around 70-75%, with potential peak revenue near ₹1,500-₹2,000 crores. Overall company growth, including Jammu, is anticipated at 25%+ for FY '26. CDMO business has shown a strong CAGR of 20%+, expected to sustain early teens growth despite pricing pressure. Domestic and international generic businesses continue to expand, with inter

Future growth expectations in earnings/operating earnings/profits/EPS?

The Jammu facility, operational from January 14, 2025, is expected to drive significant incremental revenue growth, targeting ₹400 to ₹500 crores in FY '26 and aiming for ₹1,000 crores in 2-3 years. Margins from Jammu are expected to align with existing business margins of 15-16%, with potential for slight improvement over time. Peak utilization at Jammu is expected around 70-75%, enabling revenue potential of up to ₹1,500 to ₹1,600 crores at maturity. Overall EBITDA margins may improve modestly by 100-200 basis points in the medium-term as Jammu stabilizes and benefits from GST incentiv

IN US

Sale is live|00:00:00left today

Innova Captab LtdQ4 FY26Pharmaceuticals & Biotechnology

Innova Captab Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹994P/E: 34.9Market Cap: ₹4.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Innova Captab expects continued growth driven by existing volume growth and the new Jammu facility.
→Jammu facility revenue is estimated between ₹400-₹500 crores in FY '26, with potential to reach ₹1,000 crores in 2-3 years.
→Peak utilization for Jammu plant expected around 70-75%, with potential peak revenue near ₹1,500-₹2,000 crores.
→Overall company growth, including Jammu, is anticipated at 25%+ for FY '26.
→CDMO business has shown a strong CAGR of 20%+, expected to sustain early teens growth despite pricing pressure.
→Domestic and international generic businesses continue to expand, with international growing 17% YoY.
→Sharon Bio-Medicines forecasted to grow in early teens over the coming years.
→Pricing for APIs stable Q-on-Q but slightly declined YoY; future pricing expected to stabilize.
→The company is confident of sustaining growth beyond FY '25.

Margin guidance

Category 2

→The Jammu facility, operational from January 14, 2025, is expected to drive significant incremental revenue growth, targeting ₹400 to ₹500 crores in FY '26 and aiming for ₹1,000 crores in 2-3 years.
→Margins from Jammu are expected to align with existing business margins of 15-16%, with potential for slight improvement over time.
→Peak utilization at Jammu is expected around 70-75%, enabling revenue potential of up to ₹1,500 to ₹1,600 crores at maturity.
→Overall EBITDA margins may improve modestly by 100-200 basis points in the medium-term as Jammu stabilizes and benefits from GST incentives.
→CDMO business growth is expected in the early teens percentage range, despite some year-on-year pricing pressure.
→The company remains confident in continued volume growth and stabilization of prices, supporting sustained profitability and EPS growth over coming years.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not explicitly mention any current or planned fundraising through debt or equity.
→However, the company is set to benefit from government incentive schemes, including a GST-linked incentive and a capital interest subvention on loans, which will reduce interest costs by approximately 600 basis points.
→There is discussion of investments in new facilities, such as the Jammu plant, designed to last 40-50 years, but no direct mention of new fundraising activities.
→Management refrained from giving consolidated revenue guidance, indicating a cautious outlook without highlighting specific capital-raising plans.
→Overall, there is no clear indication of imminent debt or equity fundraising in the provided content.

Order book

Yes

- The management is still working with the Business Development (BD) team on finalizing the order book for the Jammu facility. - Estimated revenue for Jammu in Q4 is expected to be in the range of ₹20 crores to ₹40 crores. - Some orders from the Sharon business were deferred from Q3 to Q4, estimated around ₹4-5 crores. - Overall, the Jammu facility is ramping up with commercial operations starting January 2025. - There is ongoing effort to maximize sales and mitigate any EBITDA costs from the new Jammu facility ramp-up. - The BD team is actively onboarding customers, mainly from existing top Indian domestic players, to increase wallet share. - Expected Jammu facility revenue next year is ₹400-500 crores, with a mix of transferred existing products and new contracts. (Information from pages 17-18 and related Q&A sections)

Capex plans

Yes

→Innova Captab has recently commercialized its Jammu facility in January 2025, representing a significant capital investment.
→The Jammu facility is expected to generate incremental revenue of ₹400-500 crores in FY26, ramping up further to peak utilization by FY28.
→The company is focused on expanding capacity and product portfolio through this new facility, with an estimated peak revenue potential of around ₹2,000 crores at full utilization.
→The Jammu facility is compliant with stringent future-ready regulations, designed with a 40-50 year vision.
→Innova Captab is eligible for Central Government incentives including a GST-linked incentive of 300% of investment in eligible plant and machinery for up to 10 years and a capital interest subvention reducing interest cost by ~600 basis points.
→There is an ongoing focus on ramping up Jammu's capacity and mitigating any ramp-up related EBITDA headwinds.

How does Innova Captab Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Innova Captab Ltd

Rev 2Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Innova Captab Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio